Abstract Background Glucagon-like peptide-1 (GLP-1) is a crucial incretin hormone secreted by intestinal endocrine L cells
Key limitations of current evidence include: Relatively short follow-up periods (typically 35 years) in randomised trials, whereas pancreatic cancer may take years to develop Potential for detection bias, as patients on GLP-1 therapy may undergo more frequent medical monitoring Difficulty accounting for all confounding factors in observational studies Despite these limitations, the weight of current evidence does not support a causal link between GLP-1 receptor agonist use and pancreatic cancer development
Beware of counterfeits While the pills may make it easier for people who need obesity care to start medication, they are also easier to counterfeit, says Chun-Su Yuan, MD, PhD, a professor in the Department of Anesthesia and Critical Care at the University of Chicago Pritzker School of Medicine
They are industrial-scale operations using automated synthesizers capable of producing multi-kilogram batches with consistent purity profiles
Conclusion In conclusion, adding high protein foods, prebiotics, healthy fats and probiotics in the diet augments the natural release of GLP-1
Reid CT, Tobin AM, Ahern T, OShea D, Kirby B
